Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
August 12 2024 - 11:00AM
Press Release – No. 8 / 2024
Zealand Pharma conference call on August 15 at 2pm CET (8am
ET) to present first half 2024 financial results
Copenhagen, Denmark, August 12, 2024 – Zealand
Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a
biotechnology company focused on the discovery and development of
innovative peptide-based medicines, announced that it will host a
conference call on August 15, 2024, at 2:00 pm CET (8:00 am ET)
following the announcement of financial results for the first half
of 2024.
Presenting during the call will be President and Chief Executive
Officer, Adam Steensberg; Chief Financial Officer, Henriette
Wennicke; and Chief Medical Officer, David Kendall. The
presentation will be followed by a Q&A session.
The live listen-only audio webcast of the call and accompanying
slide presentation will be accessible at
https://edge.media-server.com/mmc/p/ya97oe47. To receive telephone
dial-in information and a unique personal access PIN, please
register at
https://register.vevent.com/register/BI317d27d63df44f09bded2febfbe6b52a.
Participants are advised to register for the call or webcast
approximately 10 minutes before the start. A recording of the event
will be available following the call on the Investor section of
Zealand’s website at https://www.zealandpharma.com/events/.
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company focused on the
discovery and development of peptide-based medicines. More than 10
drug candidates invented by Zealand have advanced into clinical
development, of which two have reached the market and three
candidates are in late-stage development. The company has
development partnerships with a number of pharma companies as well
as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen,
Denmark, with a presence in the U.S. For more information about
Zealand’s business and activities, please visit
www.zealandpharma.com.
Contacts:
Adam Lange
(Investors) |
Investor Relations
Officer |
Zealand Pharma |
alange@zealandpharma.com |
|
Anna Krassowska, PhD
(Investors and Media) |
Vice President,
Investor Relations & Corporate Communications |
Zealand Pharma |
akrassowska@zealandpharma.com |